This is a non-cash, subsidiary-level acquisition with no immediate revenue or clinical catalyst for SciSparc. The deal adds speculative quantum analytics IP but does not change SciSparc's cash runway or near-term development timeline. Monitor NeuroThera's TSXV trading for dilution impact and any future CliniQuantum-related milestones.
Price Chart
Executive Summary
SciSparc's majority-owned subsidiary NeuroThera Labs completed the acquisition of a ~54% interest in CliniQuantum Ltd., a private Israeli quantum simulation company, for approximately CAD$9.46M in NeuroThera shares plus up to US$2.5M in earn-out payments. The deal adds a quantum-based clinical trial analytics platform but provides no near-term revenue or pipeline catalyst for SciSparc, which remains a pre-revenue clinical-stage biotech with a $5M market cap.
Key Facts
- NeuroThera Labs (TSXV: NTLX), SciSparc's majority-owned subsidiary, acquired ~54% of CliniQuantum Ltd. for 56.6M NeuroThera shares valued at ~CAD$9.46M based on 20-day VWAP.
- Earn-out payments of up to US$2.5M are contingent on patent filings and fundraising milestones over three years.
- CliniQuantum's main asset is an exclusive license to a single US provisional patent application for quantum Monte Carlo methods in clinical trial data analysis.
- The SPA was amended on April 30, 2026 to set a floor price of CAD$0.05 per share for earn-out issuances and to add lock-up arrangements for selling shareholders.
- SciSparc's market cap is ~$5M; the company had only 365,444 ordinary shares outstanding as of Dec 31, 2025 after two reverse splits.
Financial Impact
Consideration of ~CAD$9.46M in NeuroThera shares plus up to US$2.5M in contingent earn-outs. No cash consideration disclosed.
Risk Factors
- Dilution from 56.6M NeuroThera shares issued; SciSparc's indirect ownership stake in NeuroThera may be diluted if NeuroThera issues more shares for earn-outs.
- CliniQuantum is pre-revenue with only a provisional patent application — no guarantee of commercial value or regulatory acceptance of its quantum analytics approach.
- SciSparc's extremely small share count (365K shares) and $5M market cap make the stock highly volatile and susceptible to large percentage moves on low volume.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-065026 |
| Document: ea029361602ex99-1.htm | 0001213900-26-065026 |
| Document: 0001213900-26-065026-index-headers.html | 0001213900-26-065026 |
| Document: 0001213900-26-065026-index.html | 0001213900-26-065026 |
| Document: 0001213900-26-065026.txt | 0001213900-26-065026 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.29 | awaiting T+5 | — | $1.29 (−0.04%) |
Oct 23, 2026 3d ago | 6-K | $1.09 | awaiting T+5 | — | $1.29 (+18.35%) |
Oct 22, 2026 4d ago | Press Release | $1.20 | awaiting T+5 | — | $1.29 (+7.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $1.29 (+35.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 15, 2026 11d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 7, 2026 19d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $1.29 (−72.20%) |
Sep 30, 2026 26d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $1.29 (+71.65%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $1.29 (−76.07%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $1.29 (−74.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers